Trade AstraZeneca ^AZN

Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study

AstraZeneca CEO: China already a global innovation hub | govt.chinadaily.com.cn

AstraZeneca and Scientific Societies Unite for Multidisciplinary Care in Cardio-Renal-Metabolic Diseases

O Shaughnessy Asset Management LLC Cuts Stake in AstraZeneca PLC (NASDAQ:AZN)

Systems epigenetic approach towards non-invasive breast cancer detection

AstraZeneca CEO: China already a global innovation hub - Chinadaily.com.cn

OncoHelix and AstraZeneca Partner to Provide Access to Liquid Biopsy Testing for Men with Prostate Cancer

HighPoint Advisor Group LLC Sells 188 Shares of AstraZeneca PLC (NASDAQ:AZN)

Franklin Resources Inc. Buys 357,894 Shares of AstraZeneca PLC (NASDAQ:AZN)

AstraZeneca backs AI to accelerate lung cancer screening, shares evidence on impact in resource-limited settings, ET HealthWorld

FDA clears AstraZeneca's blockbuster Imfinzi for muscle-invasive bladder cancer treatment

Wellington Management Group LLP Lowers Holdings in AstraZeneca PLC (NASDAQ:AZN)

Clearbridge Investments LLC Lowers Position in AstraZeneca PLC (NASDAQ:AZN)

Summit Securities Group LLC Trims Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapy

FDA Approves AstraZeneca's Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients

AstraZeneca PLC (OTCMKTS:AZNCF) Sees Large Drop in Short Interest

AstraZeneca's Muscle-Invasive Bladder Cancer Treatment Gets FDA Approval | Morningstar

LuNGS Alliance to enhance access to tailored cancer therapies in India | Health News - Business Standard

Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism

Cancer Vaccines Market Growth Projections 2024-2034: DelveInsight Analysis | Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon, Astellas Pharma | ABNewswire

Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study

AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Orion Portfolio Solutions LLC

Modern Wealth Management LLC Buys Shares of 3,444 AstraZeneca PLC (NASDAQ:AZN)

Thrivent Financial for Lutherans Lowers Position in AstraZeneca PLC (NASDAQ:AZN)

AstraZeneca PLC (NASDAQ:AZN) Stock Position Decreased by Accent Capital Management LLC

STRIDE: Semaglutide Shows it Has Legs in Peripheral Artery Disease

Berenberg Bank Reaffirms "Buy" Rating for AstraZeneca (LON:AZN)

Frontline Fulzerasib Plus Cetuximab Elicits Deep, Durable Responses in KRAS G12C-Mutated NSCLC

Howe & Rusling Inc. Grows Position in AstraZeneca PLC (NASDAQ:AZN)

FDA Approves Imfinzi (durvalumab) for Muscle Invasive Bladder Cancer

AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | The Manila Times

Frontline Amivantamab Plus Lazertinib Significantly Reduces Mortality in EGFR-Mutant Advanced NSCLC

41,404 Shares in AstraZeneca PLC (NASDAQ:AZN) Bought by Penobscot Investment Management Company Inc.

Zions Bancorporation N.A. Raises Position in AstraZeneca PLC (NASDAQ:AZN)

J&J cancer combo reports better survival rate over AstraZeneca best-seller Tagrisso

BridgeBio Announces Approval Of Beyonttra In Japan; To Receive $30 Mln Milestone Payment

Expanding access to dialysis coverage in Mexico

J&J Passes AstraZeneca in Lung Cancer Drug Race - For Now (1)

AstraZeneca's Win in Shareholder Suit Over Viela Sale Affirmed

Bạch Mai Hospital and AstraZeneca work together to improve patient care quality

Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca | The Manila Times

Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca | Morningstar

AstraZeneca's TAGRISSO Shows Promising Results in Lung Cancer Trials

Oxidation of retromer complex controls mitochondrial translation

"Absci" Tag - The Columbian

Virtu Financial LLC Reduces Holdings in AstraZeneca PLC (NASDAQ:AZN)

Quantbot Technologies LP Has $1.30 Million Position in AstraZeneca PLC (NASDAQ:AZN)

AstraZeneca Seeks to Move Past China Probe With R&D Hub (1)

AstraZeneca puts faith in innovation - Chinadaily.com.cn

Asthma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies | ABNewswire

In a $2B deal, Novo licenses obesity drug from China's United Bio | BioWorld

After China probe, is AstraZeneca's new US$2.5 billion plan a blueprint for foreign firms? | South China Morning Post

Guardian Partners Inc. Buys Shares of 47,564 AstraZeneca PLC (NASDAQ:AZN)

AstraZeneca PLC (NASDAQ:AZN) Shares Bought by TD Private Client Wealth LLC

Prediction: 12 months from now, AstraZeneca's share price could be…

Astrazeneca invests in China: $8B in deals, $2.5B in R&D center | BioWorld

Harbour BioMed Shares Soar on News of AstraZeneca Collaboration | Morningstar

Prompt initiation of durvalumab and tremelimumab for unresectable hepatocellular carcinoma in patients with chronic active hepatitis B: a phase 2 clinical trial

Correlation of progression-free survival and overall survival after treatment for relapsed Hodgkin lymphoma: individual patient data analysis of randomized German Hodgkin Study Group (GHSG) Trials

AstraZeneca announces investment of $2.5 B to establish sixth global strategic R&D centre in China

22,614 Shares in AstraZeneca PLC (NASDAQ:AZN) Purchased by Fox Run Management L.L.C.

AstraZeneca PLC (NASDAQ:AZN) Shares Bought by Whittier Trust Co.

Pickleball Fights Severe Asthma For AstraZeneca's Fasenra 03/24/2025

British drugmaker pledges 2.5-billion USD investment in Beijing

IonQ Inc (IONQ) Showcases Quantum Computing Innovations at NVIDIA's Inaugural Quantum Day

Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC

Wall Street slides and FTSE closes lower as traders weigh up Trump tariffs, UK borrowing and Heathrow chaos

AstraZeneca invests US$2.5 billion in Beijing, undeterred by probe - The Business Times

Watch CNBC's full interview with AstraZeneca's CEO Pascal Soriot

Harbour BioMed Enters into Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Therapeutic Antibodies | The Manila Times

AstraZeneca Invests $2.5 Billion in R&D Center in China | Morningstar

AstraZeneca investing $2.5 bn in China as drugmaker seeks to recover from scandals

AstraZeneca PLC (NASDAQ:AZN) Shares Bought by HUB Investment Partners LLC

AstraZeneca investing $2.5 billion in China as drugmaker seeks to recover from scandals

Sandy Spring Bank Increases Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

Parallel Advisors LLC Decreases Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Harbour BioMed Enters Strategic Collaboration With AstraZeneca - Quick Facts

Angle PLC Announces Results of Eisai Phase 2 pilot study | Morningstar

AstraZeneca PLC (LON:AZN) Given Average Rating of "Moderate Buy" by Analysts

Astrazeneca enters multispecific antibody collaborations with CEPI, Harbour Biomed | BioWorld

AstraZeneca to establish a new global strategic R&D center in Beijing - Chinadaily.com.cn

Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals - March 21, 2025 - Zacks.com

Here's Why Parnassus Growth Equity Fund Decided to Sell AstraZeneca PLC (AZN)

William Blair Investment Management LLC Reduces Position in AstraZeneca PLC (NASDAQ:AZN)

AstraZeneca PLC (NASDAQ:AZN) Stock Holdings Raised by Boston Partners

AstraZeneca PLC (NASDAQ:AZN) Shares Bought by Connor Clark & Lunn Investment Management Ltd.

Corient Private Wealth LLC Purchases 8,894 Shares of AstraZeneca PLC (NASDAQ:AZN)

Novel selective strategies targeting the BCL-2 family to enhance clinical efficacy in ALK -rearranged non-small cell lung cancer